2024-02-15 07:57:51 ET
Summary
- Mettler-Toledo reported a -13% decline in revenue growth in Q4 FY23, with China experiencing a particularly sharp decline of 23%.
- The company managed to maintain a relatively flat adjusted operating margin through cost management efforts and strong pricing power.
- Mettler-Toledo is guiding for 1-2% revenue growth in FY24, with ongoing challenges in the Chinese healthcare industry and weak growth in the pharma and biopharma markets.
...
Read the full article on Seeking Alpha
For further details see:
Mettler-Toledo: Strong Cost Control And Pricing Growth Amid Weak Topline Growth